NCT04254471: This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients |
|
|
| Recruiting | 2/3 | 313 | RoW | AL3810, Lucitanib, E3810, E-3810, carboplatin + etoposide, Placebo | ShangHai HaiHe Pharmaceutical | Extensive-stage Small Cell Lung Cancer | 05/22 | 11/22 | | |
